Literature DB >> 7362189

Primary treatment of breast cancer by modified radical mastectomy, radiotherapy, and chemotherapy.

F D Moore.   

Abstract

Entities:  

Mesh：

Year:  1980        PMID： 7362189      PMCID： PMC2492260     

Source DB:  PubMed          Journal:  Ann R Coll Surg Engl        ISSN： 0035-8843            Impact factor:   1.891


× No keyword cloud information.
  9 in total

1.  Adrenalectomy with chemotherapy in the treatment of advanced breast cancer: objective and subjective response rates; duration and quality of life.

Authors:  F D Moore; S B VanDevanter; C M Boyden; J Lokich; R E Wilson
Journal:  Surgery       Date:  1974-09       Impact factor: 3.982

2.  Hormone receptors: their role in predicting prognosis and response to endocrine therapy.

Authors:  W L McGuire
Journal:  Semin Oncol       Date:  1978-12       Impact factor: 4.929

3.  The relation between estrogen receptors and response rate to cytotoxic chemotherapy in metastatic breast cancer.

Authors:  M E Lippman; J C Allegra; E B Thompson; R Simon; A Barlock; L Green; K K Huff; H M Do; S C Aitken; R Warren
Journal:  N Engl J Med       Date:  1978-06-01       Impact factor: 91.245

4.  The CMF program for operable breast cancer with positive axillary nodes. Updated analysis on the disease-free interval, site of relapse and drug tolerance.

Authors:  G Bonadonna; A Rossi; P Valagussa; A Banfi; U Veronesi
Journal:  Cancer       Date:  1977-06       Impact factor: 6.860

Review 5.  Current status of estrogen and progesterone receptors in breast cancer.

Authors:  W L McGuire; K B Horwitz; O H Pearson; A Segaloff
Journal:  Cancer       Date:  1977-06       Impact factor: 6.860

Review 6.  Kinetic, hormonal and clinical studies with aminoglutethimide in breast cancer.

Authors:  R J Santen; E Samojlik; A Lipton; H Harvey; E B Ruby; S A Wells; J Kendall
Journal:  Cancer       Date:  1977-06       Impact factor: 6.860

7.  L-phenylalanine mustard (L-PAM) in the management of primary breast cancer. An update of earlier findings and a comparison with those utilizing L-PAM plus 5-fluorouracil (5-FU).

Authors:  B Fisher; A Glass; C Redmond; E R Fisher; B Barton; E Such; P Carbone; S Economou; R Foster; R Frelick; H Lerner; M Levitt; R Margolese; J MacFarlane; D Plotkin; H Shibata; H Volk
Journal:  Cancer       Date:  1977-06       Impact factor: 6.860

8.  Antihormone treatment of stage IV breast cancer.

Authors:  A Manni; J E Trujillo; J S Marshall; J Brodkey; O H Pearson
Journal:  Cancer       Date:  1979-02       Impact factor: 6.860

9.  Estrogen receptors and responses to chemotherapy and hormonal therapy in advanced breast cancer.

Authors:  D T Kiang; D H Frenning; A I Goldman; V F Ascensao; B J Kennedy
Journal:  N Engl J Med       Date:  1978-12-14       Impact factor: 91.245
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.